A
IndiaDescription
Navi Mumbai group engaged in research and manufacture of pharmaceutical intermediates and specialty chemicals, with contract research and toll manufacturing from laboratory to commercial scale. States more than 500 products developed and over 60 commercialised, including intermediates for dolutegravir, empagliflozin, brexpiprazole, ibrutinib and luliconazole. One R&D centre and two production units.